LASSBio-881
 | |
| Identifiers | |
|---|---|
| PubChem | CID 16721055 |
| Chemical data | |
| Formula | C23H27N3O6 |
| Molar mass | 441.476 g/mol |
| |
LASSBio-881 is a drug which acts as both a non-selective partial agonist of the CB1 and CB2 cannabinoid receptors, and also as an antagonist of the TRPV1 receptor, as well as having antioxidant effects. It has potent anti-inflammatory and anti-hyperalgesic effects in animal studies.[1][2][3]
References
- ↑ Duarte CD, Tributino JL, Lacerda DI, Martins MV, Alexandre-Moreira MS, Dutra F, Bechara EJ, De-Paula FS, Goulart MO, Ferreira J, Calixto JB, Nunes MP, Bertho AL, Miranda AL, Barreiro EJ, Fraga CA. Synthesis, pharmacological evaluation and electrochemical studies of novel 6-nitro-3,4-methylenedioxyphenyl-N-acylhydrazone derivatives: Discovery of LASSBio-881, a new ligand of cannabinoid receptors. Bioorganic and Medicinal Chemistry. 2007 Mar 15;15(6):2421-33. PMID 17275312
- ↑ Tributino JL, Santos ML, Mesquita CM, Lima CK, Silva LL, Maia RC, Duarte CD, Barreiro EJ, Fraga CA, Castro NG, Miranda AL, Guimaraes MZ. LASSBio-881: an N-acylhydrazone transient receptor potential vanilloid subfamily type 1 antagonist orally effective against the hypernociception induced by capsaicin or partial sciatic ligation. British Journal of Pharmacology. 2010 Apr;159(8):1716-23. PMID 20401963
- ↑ Santana P et al. NEUROACTIVE PROPERTIES OF THE MULTIFUNCTIONAL PROTOTYPE LASSBio-881: FOCUS ON THE CANNABINOID SYSTEM
This article is issued from Wikipedia - version of the Saturday, April 28, 2012. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.